Dr. Amoolya Singh Honored as Exceptional Business Leader by San Francisco Business Times
BALTIMORE and PALO ALTO, Calif., May 12, 2025 /PRNewswire/ — DELFI Diagnostics, Inc., developer of innovative blood-based tests that leverage cell-free DNA (cfDNA) fragmentomics for cancer detection and monitoring, today announced that its Chief Technology Officer, Dr. Amoolya Singh, has been named to the San Francisco Business Times’ 2025 Most Influential Women in Bay Area Business list. Dr. Singh, who was previously named to this list in 2021, joined DELFI in December 2024 and has over two decades of experience working at the intersection of biotechnology and computational science. She boasts an impressive track record of developing breakthrough genomic technologies and products. As the CTO of DELFI Diagnostics, she leads the company’s strategic technology roadmap to help deliver reliable, affordable, and non-invasive tests that enhance cancer detection and transform how cancer is diagnosed and treated, particularly for high-risk patients in underserved communities.
“Amoolya excels at integrating biology and assay with computational science and software, and combines her technical skills with a collaborative approach to leadership that ensures her teams can work together to push the boundaries of science and technology and ultimately, revolutionize healthcare,” said Susan Tousi, CEO of DELFI Diagnostics. “We’re proud of this recognition and that she’s part of our team of experts working to improve the accuracy and accessibility of cancer screening.”
The San Francisco Business Times’ annual Most Influential Women in Bay Area Business list recognizes exceptional business leaders making significant contributions to their companies, industries, and communities. Dr. Singh was selected from nearly 400 nominees.
“I’m honored to be listed among these notable leaders in Bay Area business,” added Dr. Singh. “I am passionate about people and science, and my focus will always remain on making an impact in my work, while ensuring it serves others. I believe strongly in DELFI’s mission, and I am excited to advance its groundbreaking research further and reduce it to practice.”
DELFI’s AI-driven approach enables earlier intervention for high-risk populations and creates new opportunities for treatment monitoring. It is the only demonstrated approach enabling population-scale screening.
The clinically validated FirstLook Lung is DELFI’s blood test designed to improve early detection of lung cancer, which remains the leading cause of cancer deaths in the United States. DELFI also launched the DELFI-TF Assay and related services to help actively guide critical oncology drug development decisions for pharmaceutical companies. The technology is designed to deliver essential insights at every stage of the metastatic cancer journey, from baseline assessment and response monitoring to resistance detection and continuous insight across all treatment lines.
For more information about DELFI and its approach, visit www.delfidiagnostics.com.
About DELFI Diagnostics
DELFI Diagnostics is developing next-generation, blood-based tests that are accurate, accessible, and deliver a new way to help detect cancer. DELFI tests are built to solve the highest-burden population health issues, including in historically underserved demographics, and have the potential to save lives on a global scale. FirstLook Lung, for individuals eligible for lung cancer screening, is our first laboratory-developed screening test and requires a simple blood draw that can be incorporated with routine blood work. The test is based on fragmentomics, the discovery that cancer cells are more chaotic than normal cells and, when they die, leave behind tell-tale patterns and characteristics of cell-free DNA (cfDNA) fragments in the blood. The DELFI platform applies advanced machine-learning technology to whole-genome sequencing data to assess individuals’ cfDNA fragments against populations with and without cancer. FirstLook Lung uses these millions of data points to reliably identify individuals who may have cancer detected through low-dose CT, including early-stage disease, with a negative predictive value of 99.8 percent. This test has not been cleared or approved by the FDA.
SOURCE DELFI Diagnostics
